5月20日,三生制药宣布与辉瑞达成一项总额高达60.5亿美元的授权协议,将其自主研发的PD-1/VEGF双特异性抗体SSGJ-707的全球(除中国内地)开发、生产和商业化权益独家授予辉瑞,同时保留中国内地的权益。此合作消息一经发布,资本市场迅速做出反应。开盘前,三生制药股价大幅高开,报16.66港元/股。今日收盘,三生制药股价大幅高开32.28%,达19.18港元,充分体现出资本市场对此次合作的...
Source Link5月20日,三生制药宣布与辉瑞达成一项总额高达60.5亿美元的授权协议,将其自主研发的PD-1/VEGF双特异性抗体SSGJ-707的全球(除中国内地)开发、生产和商业化权益独家授予辉瑞,同时保留中国内地的权益。此合作消息一经发布,资本市场迅速做出反应。开盘前,三生制药股价大幅高开,报16.66港元/股。今日收盘,三生制药股价大幅高开32.28%,达19.18港元,充分体现出资本市场对此次合作的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.